ERBB2 and breast cancer: We have reported that RCAS carrying an activated version of ErbB2 (RCAS-caErbB2) induces mammary tumors with a median latency of 6 months in MMTV-tva mice that express tva from the MMTV promoter, which is active in the great majority of cells in the mammary epithelium [27].